- Home
- ALXO
as 05-09-2025 12:30pm EST
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 28.3M | IPO Year: | 2020 |
| Target Price: | $4.14 | AVG Volume (30 days): | 522.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.44 - $17.50 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ALX Oncology Holdings Inc. (ALXO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pons Jaume | ALXO | PRESIDENT & CSO | Feb 19 '25 | Sell | $1.15 | 1,326 | $1,525.17 | 579,388 | |
| Lettmann Jason | ALXO | CHIEF EXECUTIVE OFFICER | Feb 19 '25 | Sell | $1.15 | 2,159 | $2,483.28 | 170,270 | |
| Pinto Shelly | ALXO | SVP, FINANCE AND CAO | Feb 19 '25 | Sell | $1.15 | 550 | $632.61 | 87,352 |
Latest ALX Oncology Holdings Inc. News
ALXO Breaking Stock News: Dive into ALXO Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
7 days ago
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
MT Newswires
11 days ago
UBS Adjusts ALX Oncology Price Target to $1.20 From $2.20, Maintains Buy Rating
Clinical Trials Arena
11 days ago
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
MT Newswires
14 days ago
ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity
GlobeNewswire
14 days ago
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
MT Newswires
14 days ago
ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints
GlobeNewswire
14 days ago
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
Compare ALXO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALXO ALX Oncology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.